On Dec. 29, 2021, NRx Pharmaceuticals announced that it hds filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug Administration focused on patients with Critical COVID-19 and respiratory failure who are at immediate risk of death despite treatment with remdesivir and other approved therapies.